In 2017, cancer drugs once again dominated the news, with many of these medications making headlines for being the first of their kind to gain approval. Beyond cancer, drugs for inflammatory diseases also received attention, for both their successes and their failures.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
09 January 2018
In the December 2017 issue, the article "Drugs that made headlines in 2017" (Nat. Med. 23, 1392–1393, 2017) inaccurately described the mechanism of the RNAi drug fitusiran. The drug does not fix defective RNA code or a defective protein, but rather suppresses the production of a functional protein. The error has been corrected in the HTML and PDF versions of the article.
Rights and permissions
About this article
Cite this article
Chakradhar, S. Drugs that made headlines in 2017. Nat Med 23, 1392–1393 (2017). https://doi.org/10.1038/nm1217-1392
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1217-1392
This article is cited by
-
Correction
Nature Medicine (2018)
